Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

10x Genomics, Inc. Stock Research

TXG

41.21USD-0.14(-0.34%)Market Closed
Watchlist

Market Summary

USD41.21-0.14
Market Closed
-0.34%

TXG Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

TXG Stock Price

TXG RSI Chart

TXG Valuation

Market Cap

4.8B

Price/Earnings (Trailing)

-27.92

Price/Sales (Trailing)

8.46

EV/EBITDA

-32.57

Price/Free Cashflow

-40.86

TXG Price/Sales (Trailing)

TXG Profitability

Operating Margin

75.61%

EBT Margin

-31.69%

Return on Equity

-21.73%

Return on Assets

-17.19%

Free Cashflow Yield

-2.45%

TXG Fundamentals

TXG Revenue

Revenue (TTM)

568.4M

Revenue Y/Y

28.1%

Revenue Q/Q

9.33%

TXG Earnings

Earnings (TTM)

-172.3M

Earnings Y/Y

3.17%

Earnings Q/Q

-22.99%

Price Action

52 Week Range

23.8163.57
(Low)(High)

Last 7 days

-10.8%

Last 30 days

-13.9%

Last 90 days

-24.5%

Trailing 12 Months

42.6%

TXG Financial Health

Current Ratio

5.37

TXG Investor Care

Shares Dilution (1Y)

2.76%

Diluted EPS (TTM)

-1.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for TXG

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-14
Saxonov Serge
gifted
-
-
-3,167
chief executive officer
2023-09-14
Saxonov Serge
sold
-98,739
49.3697
-2,000
chief executive officer
2023-08-22
McAnear Justin J.
sold
-76,820
45.7811
-1,678
chief financial officer
2023-08-22
Saxonov Serge
sold
-172,000
45.7811
-3,757
chief executive officer
2023-08-22
Hindson Benjamin J.
sold
-157,899
45.7811
-3,449
see remarks
2023-08-22
Wilbur James
sold
-444,031
45.7811
-9,699
chief commercial officer
2023-08-14
Saxonov Serge
sold
-100,212
50.106
-2,000
chief executive officer
2023-08-01
Hindson Benjamin J.
sold
-433,612
62.2112
-6,970
see remarks
2023-08-01
Hindson Benjamin J.
acquired
80,015
11.48
6,970
see remarks
2023-07-19
Hindson Benjamin J.
acquired
76,491
5.4872
13,940
see remarks

1–10 of 50

Which funds bought or sold TXG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
85.62
559,000
1,208,000
-%
2023-09-12
Farther Finance Advisors, LLC
reduced
-94.94
-55,452
2,960
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-34.39
-300,751
575,152
0.01%
2023-08-21
OSAIC HOLDINGS, INC.
added
64.00
1,099,900
2,803,720
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
6.01
346,097
6,016,150
0.01%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
3,000
4,128,000
0.04%
2023-08-21
VitalStone Financial, LLC
unchanged
-
-1,000
-
-%
2023-08-16
CASTLEARK MANAGEMENT LLC
new
-
3,423,550
3,423,550
0.16%
2023-08-16
Nuveen Asset Management, LLC
reduced
-0.78
-99,014
14,219,000
-%
2023-08-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-9.21
-234,000
2,319,000
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying TXG calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TXG
No. of Funds

Schedule 13G FIlings of 10x Genomics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 10, 2023
morgan stanley
5.2%
5,139,461
SC 13G/A
Jul 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
venrock associates vi, l.p.
4.9%
4,828,247
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.81%
8,420,011
SC 13G/A
Feb 08, 2023
morgan stanley
10.4%
9,894,979
SC 13G/A
Feb 01, 2023
blackrock inc.
5.6%
5,319,179
SC 13G/A
Jan 18, 2023
baillie gifford & co
9.00%
8,602,235
SC 13G/A
Sep 12, 2022
morgan stanley
10.9%
10,341,753
SC 13G/A
May 09, 2022
blackrock inc.
10.9%
10,227,673
SC 13G

Recent SEC filings of 10x Genomics

View All Filings
Date Filed Form Type Document
Sep 18, 2023
4
Insider Trading
Sep 14, 2023
144
Notice of Insider Sale Intent
Aug 24, 2023
4
Insider Trading
Aug 24, 2023
4
Insider Trading
Aug 24, 2023
4
Insider Trading
Aug 24, 2023
4
Insider Trading
Aug 16, 2023
4
Insider Trading
Aug 04, 2023
10-Q
Quarterly Report
Aug 03, 2023
4
Insider Trading
Aug 03, 2023
8-K
Current Report

Peers (Alternatives to 10x Genomics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
32.8B
7.0B
-6.47% -9.35%
28.95
4.69
5.03% -14.68%
24.5B
4.0B
-4.51% -0.85%
27.61
6.21
2.30% 16.37%
20.8B
4.5B
-16.87% -30.97%
-4.96
4.65
-4.92% -21931.58%
16.1B
2.8B
-15.95% -22.45%
19.74
5.69
-24.31% 21.35%
16.0B
3.0B
-0.88% -1.65%
23.72
5.35
3.16% -3.93%
MID-CAP
SMALL-CAP
2.1B
146.1M
-14.72% 60.53%
-6.64
14.5
4.72% -55.19%
974.5M
112.0M
4.60% 206.26%
-14.81
8.7
0.83% 16.42%
734.8M
189.6M
-17.53% -21.85%
-3.85
3.88
18.74% 17.75%
174.6M
114.1M
-5.10% 58.53%
-32.16
1.53
-5.49% -48.58%
104.7M
99.2M
-9.09% -75.61%
-1.85
1.06
-26.56% -199.52%
99.1M
31.5M
-3.25% 60.22%
-0.68
3.14
35.12% -38.47%
78.4M
143.9M
-41.49% -87.32%
-0.47
0.54
0.71% -18.99%
72.9M
52.7M
-18.03% -31.52%
-9.65
1.38
2.10% -1984.29%
59.2M
67.1M
-18.67% -60.39%
-0.54
0.88
-12.13% -17.68%

10x Genomics News

MarketBeat
SG Americas Securities LLC Purchases 4135 Shares of 10x ....
MarketBeat,
21 hours ago
Marketscreener.com
Securities.io
Investor's Business Daily

Returns for TXG

Cumulative Returns on TXG

-30.8%


3-Year Cumulative Returns

Risks for TXG

What is the probability of a big loss on TXG?

88.3%


Probability that 10x Genomics stock will be more than 20% underwater in next one year

65.7%


Probability that 10x Genomics stock will be more than 30% underwater in next one year.

59.6%


Probability that 10x Genomics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXG drawdown profile look like?

Y-axis is the maximum loss one would have experienced if 10x Genomics was unfortunately bought at previous high price.

Drawdowns

Financials for 10x Genomics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue6.0%568,408,000536,198,000516,409,000503,707,000497,932,000499,165,000490,490,000459,178,000405,698,000332,761,000298,845,000261,916,000251,306,000264,220,000245,893,000221,158,000196,558,000172,483,000146,313,000127,678,667118,304,000
Gross Profit3.1%418,102,000405,395,000396,023,000392,550,000392,634,000416,656,000416,399,000393,788,000350,415,000272,341,000240,377,000205,763,000194,084,000202,044,000184,860,000161,807,000147,446,000133,827,000117,652,000109,330,667101,264,000
Operating Expenses2.2%596,540,000583,592,000563,967,000553,228,000529,195,000500,428,000468,652,000839,794,000845,797,000796,815,000774,519,000338,402,000270,564,000249,466,000215,433,000259,265,000250,741,000266,088,000228,416,000185,196,000-
  S&GA Expenses3.9%327,078,000314,905,000298,300,000289,290,000277,965,000267,331,000257,560,000243,657,000233,130,000208,843,000202,326,000185,108,000166,173,000154,328,000130,834,000118,984,000105,480,00097,212,00087,936,00076,440,000-
EBITDA100.0%--143,905,000-136,127,000-136,357,000-113,325,000-60,963,000-31,731,000-426,124,000-476,665,000-507,931,000-518,782,000-117,583,000-63,155,000-36,000,000-20,888,000-91,603,000-98,403,666-119,324,000-106,084,000-54,660,000-13,625,000
EBITDA Margin100.0%--0.27-0.26-0.27-0.23-0.12-0.06-0.93-1.17-1.53-1.74-0.45-0.25-0.14-0.08-0.41-0.50-0.69-0.73-0.43-0.12
Interest Expenses-28.3%263,000367,000476,000568,000673,000773,000866,000966,0001,144,0001,241,0001,682,0002,357,0002,668,0003,057,0003,079,0002,775,0002,726,0002,708,0002,409,0002,636,000-
Earnings Before Taxes1.8%-166,867,000-169,931,000-161,971,000-161,553,000-138,166,000-84,293,000-53,715,000-446,345,000-494,960,000-524,747,000-534,476,000-132,879,000-77,211,000-48,276,000-31,033,000-99,489,000-105,223,000-125,884,000-112,398,000-61,316,000-
EBT Margin100.0%--0.32-0.31-0.32-0.28-0.17-0.11-0.97-1.22-1.58-1.79-0.51-0.31-0.18-0.13-0.45-0.54-0.73-0.77-0.48-0.16
Net Income1.2%-172,290,000-174,334,000-166,000,000-167,234,000-142,491,000-89,085,000-58,223,000-455,347,000-504,024,000-533,139,000-542,731,000-134,292,000-78,047,000-48,758,000-31,251,000-99,641,000-105,383,000-100,428,000-112,485,000-49,281,333-43,232,000
Net Income Margin100.0%--0.33-0.32-0.33-0.29-0.18-0.12-0.99-1.24-1.60-1.82-0.51-0.31-0.18-0.13-0.45-0.54-0.58-0.77-0.39-0.37
Free Cashflow100.0%--125,013,000-165,267,000-161,069,000-161,376,000-128,642,000-122,651,000-252,352,000-262,047,000-286,856,000-254,564,000-102,906,000-45,920,000-18,721,000-8,115,000-61,662,000-83,346,666-106,904,000-82,693,000-39,053,333-14,455,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets-2.4%9901,0141,0299961,0021,0031,0199919789549291,04358361046.00573124
  Current Assets-3.1%583602635629666697748744757746774900452430481474106
    Cash Equivalents-2.6%33134022724228232059660964964468983440443247647770.00
  Inventory1.7%84.0082.0082.0079.0071.0064.0060.0051.0044.0039.0030.0025.0022.0019.0015.0013.009.00
  Net PPE-2.5%28529228925822319016914312210773.0065.0056.0052.0049.0047.0011.00
  Goodwill0%5.005.005.005.005.005.005.005.005.005.005.00------
Liabilities-7.2%196212223220218197201190193202190217192201186151101
  Current Liabilities-12.4%98.0011213112711894.0011010011312111814612259.0063.0048.0032.00
    LT Debt, Current---------------10.007.004.00
    LT Debt, Non Current---------------20.0022.0025.00
Shareholder's Equity-1.1%793802806776784807818800785752739825391409420421-
  Retained Earnings-5.8%-1,142-1,080-1,029-1,012-970-905-863-844-827-816-805-389-323-283-262-255-231
  Additional Paid-In Capital2.8%1,9371,8841,8391,7931,7581,7151,6811,6451,6121,5691,5441,21571569368267711.00
Accumulated Depreciation-86.00-69.00---49.0044.0039.0035.0031.00---19.00-14.00
Shares Outstanding0.9%11711611511411411311311111010910810199.0097.0096.0020.0013.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32017Q4
Cashflow From Operations32.1%-11.49-16.93-33.61-41.52-58.18-38.09-21.37-157-186-219-217-81.02-10.8723.0035.00-23.07-50.13-83.36-76.41-33.88-10.70
  Share Based Compensation6.1%16215313712311510696.0083.0071.0058.0049.0039.0030.0019.0013.009.006.004.003.002.002.00
Cashflow From Investing86.6%50.0027.00-350-345-332-319-106-101-82.46-74.63-38.39-22.71-35.08-41.48-42.77-39.01-33.78-24.39-6.71-5.17-3.76
Cashflow From Financing7.4%11.0010.0016.0020.0024.0034.0035.0034.0051450646946038938041545248.0074.0010593.0021.00

TXG Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 146,819$ 114,609$ 281,104$ 229,105
Cost of revenue47,20727,70483,10253,182
Gross profit99,61286,905198,002175,923
Operating expenses:    
Research and development71,46070,685138,558134,763
Selling, general and administrative91,51079,337174,790146,012
Total operating expenses162,970150,022313,348280,775
Loss from operations(63,358)(63,117)(115,346)(104,852)
Other income (expense):    
Interest income4,1001,2387,9691,807
Interest expense(5)(109)(24)(237)
Other expense, net(1,504)(1,843)(3,020)(2,243)
Total other income (expense)2,591(714)4,925(673)
Loss before provision for income taxes(60,767)(63,831)(110,421)(105,525)
Provision for income taxes1,6476272,7401,346
Net loss$ (62,414)$ (64,458)$ (113,161)$ (106,871)
Net loss per share, basic (in dollars per share)$ (0.53)$ (0.57)$ (0.97)$ (0.94)
Net loss per share, diluted (in dollars per share)$ (0.53)$ (0.57)$ (0.97)$ (0.94)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)116,707,672113,574,757116,166,776113,272,158
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)116,707,672113,574,757116,166,776113,272,158

TXG Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 325,879$ 219,746
Marketable securities65,506210,238
Restricted cash1,5002,633
Accounts receivable, net87,685104,211
Inventory83,68781,629
Prepaid expenses and other current assets18,68316,578
Total current assets582,940635,035
Property and equipment, net284,913289,328
Restricted cash3,4744,974
Operating lease right-of-use assets71,04969,882
Goodwill4,5114,511
Intangible assets, net22,29022,858
Other noncurrent assets20,4612,392
Total assets989,6381,028,980
Current liabilities:  
Accounts payable23,12421,599
Accrued compensation and related benefits22,37232,675
Accrued expenses and other current liabilities34,08859,779
Deferred revenue9,2177,867
Operating lease liabilities9,2869,037
Total current liabilities98,087130,957
Operating lease liabilities, noncurrent90,33186,139
Other noncurrent liabilities7,9196,141
Total liabilities196,337223,237
Commitments and contingencies (Note 4)
Stockholders’ equity:  
Preferred stock00
Common stock22
Additional paid-in capital1,936,7501,839,397
Accumulated deficit(1,142,482)(1,029,321)
Accumulated other comprehensive loss(969)(4,335)
Total stockholders’ equity793,301805,743
Total liabilities and stockholders’ equity$ 989,638$ 1,028,980
Serge Saxonov
1240
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.